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SUMMARY 
Background: Breast cancer is the leading cause of 
cancer deaths in Ghanaian women.  
Objective: To describes the characteristics of breast 
cancer patients attending the Komfo Anokye Teaching 
Hospital in Kumasi, Ghana.  
Method: The study was conducted at the Komfo 
Anokye Teaching Hospital. Between July 1st 2004 and 
June 30th 2009 patients presenting with breast lumps 
were assessed by clinical examination, imaging studies 
and pathological examination. Relevant clinical and 
pathological were recorded prospectively data on all 
patients with microscopically proven breast cancer. 
The cancers were graded according to the modified 
Bloom-Richardson system. Tissue immunoperoxidase 
stains for oestrogen, progesterone receptors and c-erb2 
oncogene were performed with commercially prepared 
antigens and reagents. 
Results: Nineteen thousand four hundred and twenty –
three (19,423) patients were seen during the study peri-
od. There were 330 (1.7%) patients with histologically 
proven breast cancer. The mean age was 49.1 years. A 
palpable breast lump was detected in 248 patients 
(75.2%). Two hundred and eighty –one patients 
(85.2%) presented with Stages III and IV , 271 (82.1 
%) invasive and 230 ( 85.2%) high grade carcinomas. 
Oestrogen and progesterone receptors were positive in 
32 and 9 cases respectively. Her2 protein was positive 
in 11 cases. 
Conclusion: In Kumasi, as in other parts of Ghana, 
breast cancer affects mostly young pre-menopausal 
who present with advanced disease. The cancers have 
unfavourable prognostic features and are unlikely to 
respond to hormonal therapy.  
 
Keywords: Breast cancer: late stage presentation: un-
favourable characteristics: Kumasi. 
 
INTRODUCTION 
In Ghana data on breast cancer is scant. However the 
disease is a common cause of hospital admissions and 
mortality among Ghanaian women.1-2 Reported clinical 
studies from Ghana and other communities in sub Sa-
haran Africa indicate that breast cancer in indigenous 
black African populations is often severe with unfa-
vourable prognostic features.3-4 Some of these features 
include young age at presentation, advanced stage at 
diagnosis, large tumour size, high grade histologic sub-
types and low rate of hormone receptor positivity.4-10 
The features are believed to explain why African wom-
en are more likely than women from the developed 
countries to die from the disease.5  
 
There are no universally acceptable explanations for 
the features that characterize breast cancer in women of 
indigenous African populations. Data from genetic, 
clinical and other studies suggest that breast cancer in 
the indigenous African women has an inherently ag-
gressive biology.11-14 Recently other reported studies 
support the contrary view that these features only re-
flect the late stage at diagnosis and the adverse influ-
ence of lack of awareness of the disease, non- availa-
bility of screening methods and some other epidemio-
logic risk factors. 15-16 Also breast cancer is considered 
to be a complex and heterogeneous disease with ethnic 
and racial variations of histologic subtypes and tumour 
behaviour. 17  
 
The nature of the disease requires that each community 
or population must define the characteristics of the dis-
ease among its people so as to able to determine the 
most suitable method to control the disease and limit 
the mortalities.18 There are some previous reports on 
breast cancer from Accra. 9,19-20 However there are no 
reported studies on breast cancer characteristics from 
Kumasi. It is against this background that this study 
was designed. This is a report on the clinical and some 
pathological characteristics of breast cancer as seen in 
our practice. It provides African–based findings that 
should contribute to the evidence required for the better 
understanding of the disease in indigenous black Afri-
can populations. In addition the data may be useful for 
policy makers who have to decide on funding for 










PATIENTS AND METHODS 
Clinical and microscopic diagnosis of breast cancer 
The study was conducted at the Komfo Anokye Teach-
ing Hospital the second largest in Ghana. The hospital 
is located in Kumasi 250 kilometres north of the na-
tional capital Accra. It runs an autonomous clinic de-
voted to breast diseases only on a daily basis. At the 
Komfo Anokye Teaching hospital – Breast Care Center 
(KATH- BCC) a detailed proforma – based history is 
taken from all patients at presentation and a complete 
clinical examination including the examination of the 
breast is also performed on these patients. All breast 
lumps were assessed by a combination of clinical ex-
amination, breast imaging (breast ultrasonography and 
or mammography) and tissue or pathologic diagnosis; 
the triple assessment. No breast imaging was done on 
patients with fumigating and ulcerating lesions. Speci-
mens for microscopic diagnoses of cancer included Fi-
ne Needle Aspiration Cytology (FNAC), core, exci-
sion, and incisional biopsies. In cases that the initial 
pathological diagnosis was done using FNAC speci-
mens, surgical excision specimens provided tissue for 
pathologic grading of the cancers.  
 
The estimations of oestrogen and progesterone recep-
tors and Her2/new protein became available from mid 
2008. Assistance from the Department of Pathology of 
the University Hospital of North Norway (UNN) made 
it possible to have immunohistochemical analysis on a 
limited number of breast cancer material from our hos-
pital. From July 1st 2004 to June 30th 2009 (five years) 
details of all patients with microscopically proven 
breast cancer were recorded in a prospective manner. 
After each consultation relevant data on the demo-
graphic characteristics, stage at presentation and tu-
mour characteristics of all patients with histological 
confirmation of breast cancer was recorded on a spe-
cially designed proforma. Cancer staging was done af-
ter relevant investigations using the American Joint 
Committee on Cancer (AJCC) 2002 system. There 
were no facilities for radioisotope bone scanning. 
 
Pathologic methods 
The tumours that were studied were graded using the 
modified Bloom-Richardson system. The scoring sys-
tem used was based on the degree of tubular formation, 
nuclear pleomorphism and mitotic count as seen on 
H&E stain. Each category was scored a maximum of 3 
points. The tumour grade of each cancer in our series 
was determined by the sum of the points. Tissue im-
munoperoxidase stains for oestrogen, progesterone and 
c-erb2 oncogene (Her2) receptors were performed. 
Commercially prepared antigens and reagents were 
used.  
 
The scoring system for ER and PR receptor status were 
based on the Quick score which scores the percentage 
of tumour cells with nuclear staining and the intensity 
of the staining. Cases were classified negative for ER 
and PR if there is less than 10% of nuclear staining of 
tumour cells. HER2/neu staining was scored based on 
membrane staining pattern (intensity and complete-
ness). Scores 0 and 1+ was classified as negative. Score 
2+ was inconclusive (weakly positive) and only 4 cases 
were in this category during this study. They were later 
classified as negative after Silver In situ hybridization 




A total of 19,423 patients were seen at the KATH- 
BCC during the study period. Microscopic diagnosis of 
breast cancer was established in 330 (1.7%) of the pa-
tients: This figure is 22.3% (one –fifth) of the 1481 ma-
lignancies diagnosed during the study period. The 
number of male breast cancers (5 or 1.5%) was consid-
ered too small for separate analysis. The demographic 
characteristics of the 330 patients are shown in Table 1. 
The frequency distribution of the patients according to 




Figure 1 Age distribution of 330 breast cancer patients. 
 
Clinical Presentation and Diagnosis 
The presenting symptoms were breast lump 248 
(75.2%), swelling of the breast 61 (18.5%), breast pain 
12 (3.6%) bloody nipple discharge 5 (1.5%), and lump 
in armpit 4 (1.2%). The duration of symptoms before 
presentation ranged from one to 82 months, with a 
mean of 13.8 months with a 95% C.I. (10.9, 16.7).  
 
Most of the tumours (119 or 36.1%) were located in the 
upper outer quadrant of the breast. The whole breast 
was involved in 71 patients or 21.5%.  
 
 





Other locations were central area or the nipple areola 
complex 55 patients or 16.7%, the lower outer quadrant 
28 patients (8.5%), upper inner quadrant 23(7.0%), the 
lower inner quadrant 22 patients (6.7%) and other less 
frequent locations 12 patients or 3.6%. 
 
Table 1 The demographic characteristics of breast 
cancer patients in Kumasi 
Variable N=330 
Age (years) 
        Range 





                 Male 




Age at menarche(years) 
           Range 
           Mean(SD)                                
 
13 to 23 
15.4(1.6) 
Age at first birth(years) 
          Range 
          Mean(SD) 
 
14 to 34 
21.3(4.7) 
Parity 
         Range 
        Mean(SD) 
 
0 to 12chidren 
4.2(2.7) 
Duration of breast  feeding 
(months) 
             Range 
             Mean 
 
 
4 to 6 
13.8(8.7) 
Menopausal status  





Level of education 
       None 
        Primary 






     Unemployed 
      Farmers 
    Trader/Artisan 







      Married 





       Urban 
       Semi urban 





Use of hormonal contraceptive 
                       Yes 




Family history of breast cancer 
              Yes 






FNAC was done in 64 patients or 19.4%, tru-cut biop-
sies in 30 patients (9.1%), excision biopsies in 96 pa-
tients (29.1%) and incisional biopsies in 140 patients 
(42.4%). Infiltrating ductal carcinoma not otherwise 
specified was the most frequent pathological type ac-
counting for 82.1% of the breast cancer material. Other 
less common pathological types were: in situ ductal 
2(0.6%), infiltrating lobular 1(0.3%), mucinous 
32(9.8%), medullary 13(3.9), adenocystic 5(1.5%) and 
papillary carcinomas 3(0.9%). There were three cases 
(0.9%) of adenosarcomas. Of the 270 patients in whom 
data on the cancer grade was available, 145 cancers 
(53.7%) were Grade III, 85 (31.5%) Grade II and 40 
(14.8%) Grade 1. High-grade tumours (Grades II and 
III) accounted for 85.2% of all the cancers. 
 
Table 2 Stage (AJCC, 2003) at presentation of 330 
breast cancer patients in Kumasi 









     Stage IIA 
         T0NIM0 
          TINIM0 
          T2N0M0 
          Total  
Stage IIB 
      T2NIM0 
      T3N0M0 













      Stage IIIA 
            T2N2M0 
            T3N1M0 
            T3N2M0 
            Total 
Stage IIIB 
            T4N1M0 
            T4N2M0 
             Total 
  Stage IIIC 














Stage VI   





Grand Total 330 100 
Many patients may have been under staged as no bone 
scans were done 
 
Biomarkers 
Immunoperoxidase nuclear staining of tumour of cells 
greater than 10% was recorded in 32 ER and 9 PR re-
ceptors and these were scored as positive. Of the 54 
breast cancer material stained for Her2 receptors 11 
showed membrane staining pattern (intensity and com-
pleteness) of a score of 3+ and were recorded as posi-
tive for Her2 receptor. A total of 54 breast cancer mate-
rials were stained for all three receptors and 23 (42.7%) 
were negative for all three receptors.  
 
 





Table 3 is a summary of the results of the immunop-
eroxidase staining for hormone receptors in 68 breast 
cancer materials.  
 
Table 3 Hormone receptor status of breast cancer 









ER 32(47.06) 36(52.94) 68(100) 
PR 9(13.24) 59(86.76) 68(100) 
Her2 11(20.37) 43(79.63) 54(100) 
Legend: ER; oestrogen receptor. PR; progesterone receptor, 
Her2; Human epidermal growth factor Receptor 2 
 
DISCUSSION 
 Most of the patients who were diagnosed with breast 
cancer in this study were young (peak age 40-49 years, 
Figure 1). Recent clinical and pathological studies from 
Sub Saharan Africa have reported similar findings.4-6,9 
From Uganda, Gakwaya and his colleagues reported 
that the peak age of the breast cancer patients that they 
studied was as low as 30-39 years.5 It is unclear why 
breast cancer patients in this and other studies from 
Sub Saharan Africa are so young. A possible explana-
tion is the population structure of most countries in the 
sub region. In Ghana less than 5% of all women are 
above 50 years21 and in Uganda only 4.2%. of all wom-
en are above 50 years.22 The findings of the study may 
not reflect a true increased incidence of breast cancer in 
young women as life expectancy in Ghana is low. Over 
two–thirds (73%) of the patients in the present report 
were pre menopausal (Table 1). This finding is charac-
teristic of breast cancer in Sub Saharan African wom-
en.23 Parkin and his colleagues in a study on African 
population of Zimbabwe in the 1990s reported some 
findings that suggested that multi-parity increased 
breast cancer risk before age 45 years but was protec-
tive after that age.24  
 
Recently Palmer and his co-workers reported the dual 
effect of parity on breast cancer risk in African–
American women which is consistent with earlier find-
ings by Parkin on African populations.24-25 In this study 
parity was high among the women and the average 
number of children per woman was 4.2 (Table1). The 
early age at first birth (Table 1) meant that many wom-
en have multiple childbirths in early life. The high pari-
ty (multiparty) among these young women may have 
increased the risk of breast cancer before age 45 years. 
These observations may explain the high incidence of 
breast cancer in premenopausal women that was rec-
orded in this series.  
 
Many patients may have been under staged as no bone 
scans were done. Furthermore the age distribution of 
breast cancer patients in this study indicates that 
programmes for breast cancer control in Kumasi 
(preventive, educational, awareness and screening) 
should be designed for and targeted to young women. 
 
The unfavourable characteristics of breast cancer pa-
tients in Kumasi are evident from the findings of this 
study. At presentation to hospital 85% of these young 
women had Stage III or IV disease (Table 2), the most 
frequent histological type of cancer was the infiltrating 
ductal carcinoma (82.1%).  
 
Similar findings have been reported from southern 
Ghana9, Nigeria4,12 and Uganda.5 These findings pro-
vide further evidence that breast cancer in indigenous 
black African populations has poor prognostic factors. 
The findings may explain why there is a disproportion-
ate mortality from breast cancer in Sub Saharan Afri-
can women when compared to the incidence and mor-
tality of the disease in Caucasian women.23 Some 
workers have suggested a genetic basis for the charac-
teristics of breast cancer seen in indigenous African 
populations.11  
  
There are few studies on hormone receptor status of 
breast cancer material in African patients due to the 
lack of the required infrastructure.15-16 In the present 
study nearly half (47.1 %) of the breast cancer material 
was oestrogen receptor positive (ER+), (Table 3). The 
conclusions that may be drawn from these findings 
have to be assessed in relation to the fact that only 20% 
of all the specimens were tested for hormone receptor 
status. Nonetheless the results of the immunohisto-
chemical analysis of breast cancer material from Ku-
masi as shown in four are comparable with previous 
reports from Accra where of the 74 tumours analysed 
43% were estrogen receptor positive.26 These findings 
on breast cancer material from Ghana do confirm the 
generally accepted reports indicating that the rate of 
estrogen receptor positive cancers in sub-Saharan Afri-
cans women is low.4,6,26-28  
 
Over a third (42.7%) of the breast cancer material ana-
lysed and reported in this study was negative for ex-
pression of oestrogen and progesterone receptors and 
HER2 protein (triple-negative breast cancer). Triple 
negative breast cancers have very unfavourable and 
aggressive clinicopatholigical features including onset 
at a younger age and high–grade tumours.17,29 The age 
distribution and grade of tumours of the patients in the 
present study (figures 1 and 3) are consistent with some 
of the features of triple negative cancers.28-29 Two re-
cent studies from sub Saharan Africa have reported 
high rates of hormone receptors in some Nigerian and 









Although researchers Adebamowo and Awaldekarim 
subsequently recommended that physicians caring for 
breast cancer patients of indigenous black African 
origin may use hormone therapy even for patients in 
whom the receptor status is unknown15,16, the weight of 
the evidence from world literature including the find-
ings of the present study is in favour of a more selec-
tive approach. Breast cancer patients of indigenous 
black African population as in Kumasi should have 
their requirements for hormonal treatment determined 
by the individual biological characteristics of their tu-
mours before the commencement of the therapy.  
 
About a half (53.3 %,) of the patients in the present se-
ries have had no education or only up to primary level 
(Table 1). Also over two–thirds (70.9%) of the women 
in this study were either unemployed or traders and ar-
tisans and hence of low socioeconomic status. As a re-
sult of low levels of formal education there is a lack of 
awareness of early warning signs of breast cancer. 
Consequently many patients delay for several months 
before presenting to hospital. The mean duration of 
symptoms before presentation to hospital in this study 
was over 12 months. There are other factors that may 
contribute to the long delay in seeking medical help for 
any breast complaints.  
 
These include the lack of any form of national breast 
cancer screening programme in Ghana, a weak health 
care system, poor access to health facilities and the ac-
tivities of faith healers and traditional and herbal prac-
titioners who may be more accessible to the population 
even in the urban and semi –urban communities (Table 
1). The combined effect of these adverse factors is the 
near complete absence of early disease in our series. As 
shown in Table 3 less than 1% of the tumours were of 
the early intra-duct or in situ carcinoma histological 
type and only 3.6% were Stage I at diagnosis (Table 2).  
 
As low levels of education and lower socioeconomic 
status have been found to be associated with advanced 
breast cancer at presentation30-31, the findings in this 
series suggest that any improvement in the levels of 
education and in the general socioeconomic conditions 
of the women in Kumasi is likely to lead to a reduction 
in the number of patients who present to the hospital 
with advanced breast cancer. 
The current study revealed that less than 2% of the pa-
tients seen at our center were proven to have cancer of 
the breast. This finding indicates that in our setting un-
selected screening for breast cancer may not be cost–
effective. Instead breast cancer programmes such as 
early detection of the disease should aim at health edu-
cation and (breast cancer) awareness creation among 
our women.  
This is likely to contribute to the effort to reduce late 
stage presentation of breast cancer in our practice. 
Some limitations of the study need to be addressed. 
There is no population-based Cancer Registry in Ku-
masi. Consequently the incidence of breast cancer in 
Kumasi could not be determined. Data on the incidence 
of breast cancer in Kumasi will be useful information 
for planning for the control of the disease. Only a lim-
ited number of breast cancer cases were subjected to 
immunohistochemical analysis. The data on hormone 
receptor status of breast cancer material and triple neg-
ative cancers from Kumasi cannot be generalized for 
the entire country. Many patients will still receive hor-
mone therapy blindly. 
CONCLUSION 
 In Kumasi most patients with breast cancer present 
late with advanced disease. The cancers have unfa-
vourable prognostic features and are unlikely to re-
spond to hormonal manipulation.  
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